Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI)

About this trial

This is a study enrolling individuals with new (less than 24 hours) cervical (neck area) spinal cord injuries to test the safety and effectiveness of an experimental drug called elezanumab. Elezanumab is a protein in the body that is able to neutralize a molecule that inhibits nerve regeneration after SCI, thus allowing nerve growth and possible functional recovery. The study includes two groups, one receiving elezanumab, the other receiving a placebo (an inactive drug used to compare the groups). This study is double-blinded, which means that neither trial participants nor the study doctors will know who will be given which study drug. If selected for the trial, participants will have a 2 in 3 chance to be in the group receiving the drug, or 1 in 3 chance to be in the group receiving a placebo. This study will compare the groups and measure any changes in arm and hand function.